Khadilkar Vaman V, Prasad Hemchand Krishna, Ekbote Veena H, Rustagi Vaishakhi T, Singh Joshita, Chiplonkar Shashi A, Khadilkar Anuradha V
Department of Growth and Pediatric Endocrine Unit, Hirabai Cowasji Jehangir Medical Research Institute, Jehangir Hospital, Pune, India.
Indian J Pediatr. 2015 May;82(5):404-9. doi: 10.1007/s12098-014-1412-9. Epub 2014 Apr 29.
To ascertain the impact of pituitary size as judged by Magnetic Resonance Imaging (MRI), on response to Growth Hormone (GH) therapy in GH deficient children.
Thirty nine children (9.1 ± 2.7 y, 22 boys) with non-acquired GH deficiency (21 Isolated GH deficiency and 18 Combined pituitary hormone deficiency) were consecutively recruited and followed up for one year. Clinical, radiological (bone age and MRI) and biochemical parameters were studied.
Children with hypoplastic pituitary (pituitary height < 3 mm) had more severe height deficit (height for age Z-score -6.0 vs. -5.0) and retardation of skeletal maturation (bone age chronological age ratio of 0.59 vs. 0.48) at baseline as compared to children with normal pituitary heights (p < 0.05 for both). After one year of GH therapy, height for age Z scores and percentage change in height for age Z scores were significantly higher in children with hypoplastic pituitaries (13.8 ± 3.6 and 28.7 % vs. 11.2 ± 4.1 and 21.4 %). Significant co-relation was observed between pituitary height and height for age Z-scores at baseline (r = 0.39, p < 0.05). The predicted adult height using Tanner Whitehouse-2 equations improved from 140.8 to 152.3 cm in children with hypoplastic pituitary when compared to an increase from 145.8 to 153.5 cm observed in children with normal pituitary height (p < 0.05).
Indian growth hormone deficient children with hypoplastic pituitary respond better to therapy with GH in short term.
通过磁共振成像(MRI)判断垂体大小对生长激素(GH)缺乏儿童GH治疗反应的影响。
连续招募39例非获得性GH缺乏儿童(9.1±2.7岁,22例男孩)(21例孤立性GH缺乏和18例垂体激素联合缺乏),并随访1年。研究临床、放射学(骨龄和MRI)及生化参数。
与垂体高度正常的儿童相比,垂体发育不全(垂体高度<3mm)的儿童在基线时身高缺陷更严重(年龄别身高Z评分-6.0对-5.0),骨骼成熟延迟(骨龄与实际年龄之比0.59对0.48)(两者p<0.05)。GH治疗1年后,垂体发育不全儿童的年龄别身高Z评分及年龄别身高Z评分的变化百分比显著更高(13.8±3.6和28.7%对11.2±4.1和21.4%)。在基线时观察到垂体高度与年龄别身高Z评分之间存在显著相关性(r = 0.39,p<0.05)。与垂体高度正常儿童从145.8cm增加到153.5cm相比,垂体发育不全儿童使用Tanner Whitehouse-2公式预测的成人身高从140.8cm提高到152.3cm(p<0.05)。
印度垂体发育不全的生长激素缺乏儿童短期对GH治疗反应更好。